IDEMIA
15.10.2018 16:55:43 CEST | Business Wire | Press release
The supervisory board of IDEMIA, the global leader in Augmented Identity, has appointed Yann Delabrière to be Chief Executive Officer with immediate effect taking over from Didier Lamouche who has resigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005635/en/
One year after the successful coming together of Oberthur Technologies (OT) and Safran I&S (Morpho) that gave rise to IDEMIA, Yann Delabrière will be charged with overseeing a new phase in the Group’s growth.
Yann Delabrière, who previously served as CEO of Faurecia followed by CEO of Zodiac Aerospace, was appointed IDEMIA’s supervisory board chairman in January 2018. Since then he has gained in-depth understanding of the Company’s operations and people. IDEMIA will now look to benefit from Yann’s extensive international managerial experience.
Yann Delabrière stated: “I am delighted that the Supervisory Board is entrusting me with this new role, and am excited to be leading IDEMIA as it enters the next phase of its development. IDEMIA has developed cutting-edge technologies and services leveraging artificial intelligence, biometrics and cryptography. This makes IDEMIA a major technological player in the fields of identity management and authentication or security of payments. I have witnessed IDEMIA’s growth potential first hand and believe it is excellently poised to continue to consolidate its position as the leader in the sector”
Didier Lamouche added: “During almost six years at the helm of Oberthur Technologies (OT) then IDEMIA, I am extremely proud to have contributed to building, with the teams, what has become the global leader of Augmented Identity. Together, we achieved numerous commercial successes and brought to market significant innovations, not only in the financial sector, but also with access solutions combining biometrics and remote secure communication. The successful integration of both companies, OT and Morpho, fueled by solid operational results, opens a bright future to IDEMIA and all its employees. I wish them all every success.”
Notes to Editors
About Yann Delabrière
Yann Delabrière is a graduate of the Ecole
Normale Supérieure, the Ecole Nationale d’Administration (the French
National School of Administration) and has a post-graduate degree in
mathematics. He began his career at the Committee of Public Accounts
before working in the cabinet office of the Foreign Trade Ministry. He
then worked as Financial Director of COFACE (Compagnie Française
d’Assurance pour le Commerce Extérieur, a French export credit agency)
and for the Printemps Group. In 1990, he joined the PSA Peugeot Citroën
Group as Chief Financial Officer and, in this role, became a member of
the automaker’s Executive Committee in 1998, and Chairman and CEO of the
Group’s consumer finance unit, Banque PSA Finance. Yann Delabrière was
appointed as Chairman and Chief Executive Officer of Faurecia in 2007.
He was also Chairman of the Executive Board of Zodiac Aerospace between
June 2017 and February 2018. He has been a member of the Board of
Directors of Cap Gemini from 2004 to May 2018, a member of the Board of
Directors of Société Générale from 2012 to 2016, and member of the Board
of Directors of Alstom since March 2017. He has headed IDEMIA’s
Supervisory Board since January 2018.
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to provide a secure environment enabling citizens and
consumers alike to perform their daily critical activities (such as pay,
connect, travel and vote), in the physical as well as digital space.
Securing
our identity has become mission critical in the world we live in today.
By standing for Augmented Identity, we reinvent the way we think,
produce, use and protect this asset, whether for individuals or for
objects. We ensure privacy and trust as well as guarantee secure,
authenticated and verifiable transactions for international clients from
Financial, Telecom, Identity, Public Security and IoT sectors.
OT
(Oberthur Technologies) and Safran Identity & Security (Morpho) have
joined forces to form IDEMIA. With close to $3 billion in revenues and
14,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005635/en/
Contact:
IDEMIA Press Hanna Sebbah: idemia@havas.com +33 (0)6 63 73 30 30
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
